DIUPRES-250 Drug Patent Profile
Which patents cover Diupres-250, and when can generic versions of Diupres-250 launch?
Diupres-250 is a drug marketed by Merck and is included in one NDA.
The generic ingredient in DIUPRES-250 is chlorothiazide; reserpine. There is one drug master file entry for this compound. Additional details are available on the chlorothiazide; reserpine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DIUPRES-250?
- What are the global sales for DIUPRES-250?
- What is Average Wholesale Price for DIUPRES-250?
Summary for DIUPRES-250
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 15 |
| DailyMed Link: | DIUPRES-250 at DailyMed |
US Patents and Regulatory Information for DIUPRES-250
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | DIUPRES-250 | chlorothiazide; reserpine | TABLET;ORAL | 011635-003 | Aug 26, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
